share_log

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27

HC Wainwright & Co.维持对Viridian Therapeutics的买入,将目标股价下调至27美元
Benzinga ·  05/09 15:03

HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $37 to $27.

HC Wainwright & Co. 分析师道格拉斯·曹维持Viridian Therapeutics(纳斯达克股票代码:VRDN)的买入并将目标股价从37美元下调至27美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发